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Abstract 28 
Pigs are the natural hosts of Chlamydia suis, the only Chlamydia species known to 29 
spontaneously acquire homotypic resistance conferred by a class C tetracycline resistance 30 
gene. Various susceptibility assays have existed for several years, but there is no widely 31 
accepted, standardized assay to determine chlamydial antibiotic susceptibility. In this study, 32 
we developed new approaches to determine the in vitro susceptibility of Chlamydia to 33 
different antibiotics in view of existing protocols. Specifically, the minimal inhibitory 34 
concentration (MIC) is based on a consensus of both inclusion number reduction and 35 
alteration of inclusion size and morphology upon antibiotic exposure. In addition to these, we 36 
employed a recovery assay, allowing observation of the chlamydial response to drug removal 37 
and subsequent recovery, as compared to both continued exposure and to the unexposed 38 
control. We propose a simple and fast screening method to detect tetracycline resistant C. suis 39 
strains within two to three days with minimal use of consumables. For proof of principle, we 40 
evaluated the susceptibility of three C. suis field strains and the reference strain S45/6 to 41 
tetracycline, sulfamethoxazole and penicillin, antibiotics commonly used to prevent 42 
respiratory and gastrointestinal diseases on fattening pig farms. We found that tetracycline 43 
sensitive strains can easily be distinguished from resistant strains using the evaluation 44 
parameters proposed in this study. Moreover, we report that S45/6 is sensitive to 45 
sulfamethoxazole while all evaluated C. suis field strains showed some degree of 46 
sulfamethoxazole resistance. Finally, we confirm that Penicillin G induces the chlamydial 47 
stress response in all evaluated C. suis strains. 48 
 49 
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53 
Introduction 54 
In vitro susceptibility assays are essential to detect antibiotic resistance in Chlamydia. 55 
Protocols have existed since the 1980s (Henning and Krauss, 1986), but unlike the 56 
standardized tests that are in place for extracellular and facultative intracellular bacteria 57 
(CLSI, 2012; Jorgensen and Turnidge, 2015), there is no clear consensus among the research 58 
community for antibiotic resistance determination in obligate intracellular bacteria such as 59 
Chlamydia. Table 1 summarizes previously reported protocols and/or definitions to determine 60 
the antibiotic susceptibility in Chlamydia.  61 
The aim of this study was to investigate new approaches to determine the in vitro 62 
susceptibility of Chlamydia to different antibiotics. To achieve this goal, the parameters were 63 
defined based on consideration of existing protocols (Table 1). Chlamydia (C.) suis was 64 
selected as a model for other Chlamydia species because of its high degree of genetic 65 
diversity and because it is the only example of homotypic resistance to antibiotics among the 66 
Chlamydia, which is conferred by an acquired resistance gene (Borel et al., 2016; Joseph et 67 
al., 2016; Lenart et al., 2001; Sandoz and Rockey, 2010; Schautteet and Vanrompay, 2011; 68 
Seth-Smith et al., 2017). This gene is located within a genomic island carrying a class C 69 
tetracycline resistance gene and can be transferred to other C. suis but also to and among 70 
C. trachomatis upon simultaneous co-infection in vitro (Jeffrey et al., 2013; Marti et al., 2017; 71 
Suchland et al., 2009). This could have serious implications for human health considering that 72 
the DNA of both C. suis and C. trachomatis has been detected in the eye of trachoma patients 73 
in Nepal, and that C. suis could be isolated from samples of pig farmers and slaughterhouse 74 
workers originating from various anatomical locations (conjunctiva, nose, pharynx and stool 75 
samples) (Dean et al., 2013; De Puysseleyr et al., 2014, 2015). Apart from tetracycline 76 
resistance in C. suis, induced resistance to antibiotics (e.g., rifamycins, fluoroquinolones) 77 
through point mutations has also been reported in C. suis and other Chlamydia (e.g., 78 
C. trachomatis, C. pneumoniae, C. psittaci, C. muridarum and C. caviae) following 79 
propagation at sub-inhibitory concentrations of the drug in vitro (Sandoz and Rockey, 2010). 80 
Moreover, heterotypic resistance in various Chlamydia species has been observed upon 81 
survival of a small proportion of bacteria exposed to antibiotic concentrations well above the 82 
minimal inhibitory concentration (MIC) and might be a cause of treatment failure in patients, 83 
a phenomenon also referred to as drug indifference, tolerance or persistence (Sandoz and 84 
Rockey, 2010; Suchland et al., 2003). In Chlamydia, persistence, or the chlamydial stress 85 
response, is known to occur specifically upon exposure to antibiotics affecting cell wall 86 
synthesis, such as penicillin (Borel et al., 2014; Leonard et al., 2017; Lewis, 2007; Sandoz 87 
and Rockey, 2010; Schoborg, 2011; Xue et al., 2017; Zheng et al., 2015).  88 
In the present study, the MIC was determined according to the methods described by 89 
Donati and colleagues (2010) (MIC = ≥ 90% inclusion number reduction) and by Suchland 90 
and colleagues (2003) (transition point MIC [MICTP] = ≥ 90% alteration of size/morphology; 91 
MIC = 2x MICTP). Following the determination of MIC (Donati) and MIC (Suchland), an 92 
MIC consensus was established if they were identical. Otherwise, an MIC range was 93 
determined unless the MICs were notably different. In addition, instead of applying the 94 
generally used protocols to determine the minimal bactericidal/chlamydicidal/lethal 95 
concentration (MBC/MCC/MLC), we incorporated an assay based on protocols used to 96 
evaluate recovery from the chlamydial stress response (Kintner et al., 2014; Leonard et al., 97 
2015, 2017). With this recovery assay, it is possible to evaluate the in vitro behavior of 98 
chlamydial strains upon recovery and continued exposure to low, moderate and high 99 
concentrations of the antibiotic in question instead of evaluating a single value that is identical 100 
to or only a few twofold dilutions higher compared to the determined MIC value as often 101 
observed for MBC/MCC/MLC (Agacfidan et al., 1993; Donati et al., 2010; Ehret and Judson, 102 
1988; Henning and Krauss, 1986; Japan Society of Chemotherapy, 1992a, 1992b; Suchland et 103 
al., 2003; Webberley et al., 1987).  104 
In summary, we propose a two-step protocol evaluating two major parameters, the 105 
MIC and the recovery. This approach allows initial assessment after two workdays, and a 106 
detailed report after eight workdays (Fig. 1). For proof of principle, we investigated the 107 
susceptibility of three C. suis field strains and the reference strain S45/6 to tetracycline, 108 
sulfamethoxazole and penicillin.  109 
 110 
 111 
Material and Methods 112 
The detailed in vitro antibiotic susceptibility assay protocol (tetracycline, 113 
sulfamethoxazole and PenG) is available as Supplemental Material (Text S1), and includes 114 
suggestions regarding optimization of this assay. 115 
 116 
Host cells and media 117 
LLC-MK2 cells (Rhesus monkey kidney cell line, provided by IZSLER Brescia, Italy) 118 
were grown in antibiotic-free growth medium consisting of 500 ml Eagle’s minimum 119 
essential medium (EMEM, Gibco, Thermo Fisher Scientific, Invitrogen, Carlsbad, CA, USA) 120 
supplemented with 10% heat-inactivated fetal calf serum (FCS, BioConcept, Allschwil, 121 
Switzerland), 5 ml L-glutamine (Gibco, Thermo Fisher Scientific) and 6 ml glucose 122 
(0.06 g/ml; Sigma-Aldrich Co., St. Louis, MO, USA). Following infection, growth medium 123 
was replaced by Chlamydia cultivation medium consisting of 500 ml EMEM supplemented 124 
with 20% FCS (BioConcept), 5 ml L-glutamine (Gibco, Thermo Fisher Scientific) and 2 g 125 
glucose (Sigma-Aldrich) with or without 0.7 ml cycloheximide (1 mg/ml; Sigma-Aldrich) as 126 
described (Donati et al., 2010; Wanninger et al., 2016). 127 
 128 
Chlamydial strains 129 
Four C. suis strains were used for this study: three field strains (SWA-14, 86 and 141), 130 
all isolated from fecal swabs of asymptomatic fattening pigs (Hoffmann et al., 2015; 131 
Wanninger et al., 2016) and the C. suis reference strain S45/6, which was originally isolated 132 
from feces of an asymptomatic pig (Kaltenboeck et al., 1993; Schautteet and Vanrompay, 133 
2011) (Table 2). Stocks were prepared and stored in sucrose phosphate glutamate (SPG) at -134 
80°C (218  mM sucrose [Sigma-Aldrich], 3.76  mM KH2PO4 [Sigma-Aldrich], 7.1  mM 135 
K2HPO4 [Merck Eurolab AG, Dietlikon, Switzerland], and 5  mM GlutaMAX-100 [GIBCO]) 136 
as described (Leonard et al., 2016) with minor changes: After infected cells were scraped, 137 
mechanical disruption was performed by vortexing with 10-20 glass beads (∅ 5mm) for 138 
1 min followed by pushing the suspension through a 20 Gauge needle with a 20 ml syringe. 139 
 140 
Antibiotic reagents 141 
Tetracycline hydrochloride powder (Sigma-Aldrich) was dissolved in deionized water 142 
to reach a final concentration of 10 mg/ml, filter-sterilized with a 0.22 µm syringe filter, 143 
aliquoted and stored at -20°C. Sulfamethoxazole (Santa Cruz Biotechnology, Dallas, TX, 144 
USA) stocks were prepared in DMSO (Sigma-Aldrich) with a final concentration of 145 
50 mg/ml, filter-sterilized and stored as described for tetracycline. PenG (sodium salt, Sigma-146 
Aldrich) stocks were prepared as described (Leonard et al., 2016) with a stock concentration 147 
of 20,000 U/ml in deionized water. 148 
 149 
Important definitions and parameters 150 
The Minimal inhibitory concentration (MIC) is defined as the consensus of the MIC 151 
defined by Donati and colleagues ((2010); MIC Donati ≥ 90% inclusion number reduction) 152 
and Suchland and colleagues ((2003); MIC Suchland ≥ 90% inclusions altered in size and 153 
morphology) unless one parameter could not be employed. In the recovery assay, chlamydial 154 
recovery upon drug-removal (rec) at 48 hours (h) is compared to both, continued exposure for 155 
96 h (exp) and an untreated control (mock) following determination of the number of 156 
inclusion forming units (IFU)/ml (semi-quantitative analysis) and is expressed through three 157 
parameters. 1) The resistance potential represents how well Chlamydia resist continuous 158 
exposure to the antibiotic in question (exposure to mock). In detail, it provides the highest 159 
antibiotic concentration where a) >25% or b) >10% of continuously infected cultures remain 160 
infectious compared to untreated controls. 2) The recovery potential represents how well 161 
Chlamydia recover from antibiotic treatment (recovery to mock). It provides the highest 162 
antibiotic concentration where a) >1% or b) >10% of cultures remain infectious following 163 
recovery compared to the mock-exposed cultures. Finally, 3) Survival after continued 164 
exposure directly compares the infectivity of continuously exposed to recovered cultures 165 
(exposure to recovery) and provides the highest antibiotic concentration where a) >1% or b) 166 
>10% of continuously infected cultures remain infectious compared to the recovery data of 167 
the same antibiotic concentration. 168 
 169 
 170 
Overview of the in vitro antibiotic susceptibility assay 171 
The protocol can be performed within two weeks and consists of a) determination of 172 
the initial susceptibility phenotype, b) MIC confirmation and c) the recovery assay. In the first 173 
week, the initial susceptibility phenotype and the first part of the recovery assay can be 174 
performed within 48 h and 96 h, respectively. In the second week, MIC confirmation and the 175 
second part of the recovery assay are performed within two workdays. Because all samples 176 
required for the second week are stored frozen by the end of the first week, this provides a 177 
convenient potential stopping point in the protocol. Immunofluorescence microscopy analysis 178 
can be performed on the third day (Fig. 1). For tetracycline, there is the possibility to initially 179 
perform a tetracycline resistance screen (Tet screen) for a large number of strains within a 180 
short period of time with minimal use of consumables. 181 
 182 
Determination of the initial susceptibility phenotype 183 
A Chlamydia/cell suspension was prepared for each C. suis strain containing 300,000 184 
cells per ml cycloheximide-free Chlamydia cultivation medium and a multiplicity of infection 185 
(MOI) of 0.5. 100 µl per well of this suspension was added directly to 100 µl of 186 
cycloheximide-free Chlamydia cultivation medium containing a serial dilution of antibiotics 187 
in a 96-well plate (30,000 cells per well). For tetracycline, the final antibiotic concentrations 188 
ranged from 0.0078 to 8 µg/ml (2-fold dilution); for sulfamethoxazole (or other antibiotics 189 
with an unknown susceptibility range), concentrations ranged from 4.9E-4 to 1024 µg/ml (2-190 
fold dilution); for PenG (and presumably appropriate for most or all known inducers of the 191 
classic chlamydial stress response), the final concentrations ranged from 0.01 U/ml to 100 192 
U/ml in a 10-fold dilution series. For all antibiotics evaluated, an unexposed control (mock) 193 
containing only cycloheximide-free medium was added. Moreover, each strain was assayed in 194 
duplicate. Following centrifugation (1 h, 1000g, 25°C), cultures were incubated at 37°C with 195 
5 % CO2 for 34 h before they were fixed in -20°C-chilled methanol for 10 min and 196 
immunolabeled according to the protocol described below. MIC determination was performed 197 
according to MIC (Donati). If an estimate regarding inclusion number reduction was not 198 
possible (e.g., sulfamethoxazole), MIC (Suchland) was employed instead. 199 
 200 
Recovery assay protocol 201 
Cultures were performed identically to the initial susceptibility phenotype. After 202 
incubation for 48 h instead of 34 h, culture supernatants were removed and monolayers were 203 
washed twice with antibiotic- and cycloheximide-free medium before addition of medium 204 
(150 µl) either without antibiotics (recovery) or with serially diluted antibiotics (continued 205 
exposure). After another incubation period (96 h post infection), samples were scraped into 206 
the supernatant and frozen at -80°C until use. For tetracycline, 0.03, 0.5, 2 µg/ml exposed 207 
samples and the unexposed mock control were collected both for recovery and continued 208 
exposure groups. Alternatively, 0.125 instead of 0.03 µg/ml could be collected. For 209 
sulfamethoxazole, 2, 32, 512 µg/ml exposed samples and the unexposed mock control were 210 
similarly collected. For penicillin, 1, 10, 100 U/ml exposed samples and the unexposed mock 211 
control were similarly collected. In total, each strain resulted in eight samples for IFU/ml 212 
determination per antibiotic agent (including mock). For antibiotics being evaluated for the 213 
first time, the general suggestion is that samples should be generated close to the lowest and 214 
the highest initially determined MIC, as well as including an intermediate concentration in 215 
order to evaluate the entire susceptibility range.  216 
In the second week, samples were inoculated in duplicate onto 24-well plates 217 
containing coverslips of cells cultured to confluence. Following centrifugation (1 h, 1000g, 218 
25°C), inocula were replaced by 1 ml cycloheximide-containing Chlamydia cultivation 219 
medium. Monolayers inoculated with samples from the continuously exposed condition 220 
(including mock) were additionally washed twice with medium to remove residual drugs. 221 
Inoculation volumes were established for each antibiotic and generally consisted of 1 µl of 222 
1 ml total sample volume for the mock controls (details shown in Text S1). For resistant 223 
strains (determined according to the initial susceptibility phenotype) 1 µl, 10 µl and 60 µl 224 
were generally inoculated for low, intermediate and high concentrations, respectively. For 225 
sensitive strains (according to the initially determined phenotype), 1 or 10 µl inocula were 226 
used for samples, which exhibited recovery from low antibiotic concentrations (MIC or 227 
below) and 60 µl for all other conditions/samples. Following fixation in methanol and 228 
immunofluorescence assay, the IFU/ml for each condition (recovery, or continued exposure 229 
for mock and antibiotic concentrations) was determined according to previously published 230 
methods (Deka et al., 2006). a) The resistance potential, b) the recovery potential and c) 231 
survival after continued exposure was determined as described above (“Important definitions 232 
and parameters”). 233 
 234 
MIC confirmation 235 
MIC confirmation was performed in the second week. Prepared host cell monolayers 236 
on glass coverslips in 24-well plates (150,000 cells per well) were infected with an MOI of 237 
0.1 in 1 ml cycloheximide-containing Chlamydia cultivation medium. Following 238 
centrifugation (1 h, 1000g, 25°C), inocula were replaced with 1 ml cycloheximide-containing 239 
Chlamydia cultivation medium either without (mock) or with antibiotics close to the MIC. For 240 
tetracycline, 0.03, 0.125 and 0.5 µg/ml were used; for sulfamethoxazole, 64, 128 and 256 241 
µg/ml were used for the field strains, and for S45/6, in addition to these concentrations, 242 
0.0039, 0.0078 and 0.015 µg/ml were tested; for PenG, 1, 10 and 100 U/ml was used. 243 
Following incubation for 34 h (tetracycline) or 48 h (sulfamethoxazole, penicillin), 244 
monolayers were fixed in methanol and immunofluorescence assay was performed. MIC 245 
determination was performed according to definitions by Donati et al. (2010) and Suchland et 246 
al. (2003) as described above.  247 
In detail, the average number of inclusions per 20x field was determined and 248 
compared to the mock for MIC (Donati). The lowest antibiotic concentration, where 10% or 249 
less inclusions were present compared to the mock, was defined as the MIC.  250 
For MIC (Suchland), the MIC was based on two different criteria: inclusion size and 251 
morphology, neither of which can be as easily quantified as the inclusion number due to 252 
possible variability. Despite this drawback, MIC determination was possible as the change 253 
from normal to altered inclusions in 90% of the inclusions was abrupt rather than gradual. In 254 
order to quantify this change, we semi-quantitatively determined the mean inclusion size. For 255 
that, 50 randomly selected inclusions were evaluated in at least 10 fields (400x magnification) 256 
per condition and the area (in µm2) was calculated using BonTec measuring and archiving 257 
software (BonTec, Bonn, Germany). Representative microscopic images were captured using 258 
BonTec software (BonTec) and a UI-2250SE-C-HQ camera (uEye, IDS Imaging 259 
Development Systems GmbH, Obersulm, Germany) as described previously (Leonard et al., 260 
2015). For conditions with only few or very small inclusions, up to 20 inclusions were 261 
analyzed for size and morphology if possible. In parallel, we qualitatively evaluated inclusion 262 
morphology. The following criteria were used to classify the inclusion morphology as altered 263 
compared to control inclusion morphology: size and/or the presence of aberrant bodies (ABs, 264 
aberrant inclusion bodies; diameter ≥ 2 µm, (Matsumoto and Manire, 1970)). Micro-265 
inclusions were defined as inclusions with an area of less than 15 µm2. In the case of 266 
discrepancies between these parameters, we reported susceptibility ranges (e.g., 64-128 267 
µg/ml). 268 
 269 
Tetracycline resistance screen (Tet Screen) 270 
With this method, up to ten strains per 24-well plate can be tested for tetracycline 271 
susceptibility. A tetracycline sensitive and a resistant control should be included. Two wells 272 
of a 24-well plate with confluent monolayers (150,000 cells/well) on glass coverslips are 273 
infected with an MOI of approximately 0.5 for each strain. Following centrifugation (1 h, 274 
1000g, 25°C), inocula are replaced with 1 ml of cycloheximide-containing medium either 275 
with or without 0.125 or 0.5 µg/ml tetracycline. After 34 h of incubation, monolayers are 276 
fixed in methanol, immunolabeled and tested for the presence or absence of inclusions in 277 
tetracycline-containing conditions. If inclusions in tetracycline-exposed cultures are 278 
comparable to the corresponding unexposed-control, in terms of inclusion number and 279 
morphology, the strain is considered tetracycline resistant. Complete absence of inclusions 280 
upon tetracycline exposure indicates that the strain is tetracycline sensitive. Strains falling in 281 
between these categories (“intermediate”) should be further analyzed with the in vitro 282 
susceptibility assay protocol described above. 283 
 284 
Immunofluorescence analysis (IFA) 285 
Inclusions and cell nuclei were visualized as described previously (Leonard et al., 286 
2016). Briefly, primary Chlamydiaceae family-specific mouse monoclonal antibody directed 287 
against the chlamydial lipopolysaccharide (LPS, Clone ACI-P; Progen, Heidelberg, Germany; 288 
1:200) and secondary Alexa Fluor 488-conjugated secondary goat anti-mouse antibody 289 
(Molecular Probes, Eugene, OR, USA; 1:500) were used to label inclusions. Host and 290 
chlamydial DNA were labeled with 1 µg/ml 4′,6-diamidino-2′-phenylindole dihydrochloride 291 
(DAPI, Molecular Probes). If applicable (for MIC confirmation and recovery assay), 292 
coverslips were mounted with FluoreGuard mounting medium (Hard Set; ScyTek 293 
Laboratories Inc., Logan, UT, USA) on glass slides. All coverslips were analyzed with a 294 
Leica DMLB fluorescence microscope (Leica Microsystems, Wetzlar, Germany), while 96-295 
well plates were analyzed with a Nikon Eclipse Ti microscope (Nikon, Tokyo, Japan).  296 
 297 
Transmission electron microscopy (TEM) 298 
TEM images were produced according to previously published methods (Leonard et 299 
al., 2016). Ultrathin (80 nm) sections were mounted on gold grids (Merck) and contrasted 300 
with uranyl acetate dehydrate (Fluka; Sigma-Aldrich) and lead citrate (Merck). Sections were 301 
subsequently evaluated using a Philips CM10 electron microscope (Software release version 302 
5.1; FEI Company, Hillsboro, OR, USA) and imaged using a Gatan Orius SC 1000 CCD 303 
Camera with software version Digital Micrograph 2.30 (Gatan Inc., Warrendale, PA, USA). 304 
 305 
Statistical analysis 306 
Unless stated otherwise, results were displayed as means ± standard deviation, of the 307 
results from 2 or 3 independent experiments. Statistical significance of the difference of 308 
means was determined by Student’s t-test and Welch t-test (t-test unequal variance) using 309 
GraphPad QuickCalcs Web site: http://www.graphpad.com/quickcalcs/ttest1/ (accessed 310 
January 2018) and the Excel software. p-values of <0.05 were considered significant.  311 
 312 
 313 
Results 314 
 315 
Tetracycline susceptibility can be determined using multiple evaluation parameters  316 
 317 
Initial susceptibility phenotype and MIC determination 318 
The initial tetracycline susceptibility phenotype of four C. suis strains (field strains 319 
SWA-14, SWA-86 and SWA-141, and reference strain S45/6), all originally isolated from 320 
farmed pigs, was determined after two to three workdays. This was accomplished by 321 
simultaneously seeding and infecting LLC-MK2 cells with Chlamydia in cycloheximide-free 322 
medium with two-fold tetracycline dilutions (Week 1, Table 3) and determining the MIC as 323 
described by Donati et al (2010) (Table 3). In confirmation of previously published results 324 
(Dugan et al., 2004), and in accord with tetracycline susceptibility definitions described 325 
(Wanninger et al., 2016), S45/6 was sensitive to tetracycline (MIC < 2 µg/ml). Amongst the 326 
field strains, SWA-141 was resistant (MIC ≥ 4 µg/ml), and SWA-14 and SWA-86 were 327 
sensitive, and no strain showed intermediate tetracycline susceptibility 328 
(2 µg/ml  ≤ MIC < 4 µg/ml) (Dugan et al., 2004; Wanninger et al., 2016). The MIC was 329 
confirmed by infecting confluent host cell monolayers in the presence of tetracycline 330 
concentrations several two-fold dilutions above and below the initially determined MIC in 331 
cycloheximide-containing medium (Week 2, Table 3). MIC determination was performed 332 
both according to Donati et al. (2010) and Suchland et al. (2003) to establish the MIC 333 
consensus. Cycloheximide was not added in the first week to ensure cellular growth upon 334 
simultaneous seed and infection, while it was added in the second week to a) analyze whether 335 
cycloheximide potentially influences the susceptibility of Chlamydia to tetracycline and other 336 
antibiotics and b) to avoid overgrowth of the cell monolayers. 337 
 338 
Inclusion size analysis 339 
Considering data provided by Suchland et al. (2003), a reduction in inclusion numbers 340 
can be expected to be preceded or accompanied by altered inclusion size and/or morphology. 341 
In order to quantify and further confirm the MIC (Suchland), we analyzed the average 342 
inclusion size for each strain at 0.03 µg/ml, 0.125 µg/ml and 0.5 µg/ml tetracycline. We 343 
clearly observed that the average inclusion size of all three tetracycline sensitive strains 344 
(SWA-14, SWA-86, S45/6) was significantly reduced at tetracycline concentrations as low as 345 
0.03 µg/ml, while the average inclusion size of tetracycline resistant SWA-141 exposed to 346 
≤ 0.5 µg/ml tetracycline was similar to the unexposed control (mock, Fig. 2). 347 
 348 
Tetracycline resistance screen (Tet Screen) 349 
The observed variation in inclusion size in tetracycline resistant versus sensitive 350 
strains led us to hypothesize that it might be possible to easily distinguish resistant from 351 
sensitive strains by comparing the unexposed controls to cultures exposed to 0.125 µg/ml or 352 
0.5 µg/ml tetracycline, which would allow screening of a large number of strains in less than 353 
48 h post infection (hpi). Fig. 3 shows that the inclusion number and size/morphology of the 354 
tetracycline resistant strain SWA-141 was similar regardless of tetracycline concentration, 355 
while no or only micro-inclusions (area less than 15 µm2) were visible in tetracycline-exposed 356 
cultures infected with tetracycline sensitive SWA-14, 86 or S45/6. To further confirm our 357 
hypothesis, we screened additional previously reported tetracycline resistant (5-27b, 1-28b, 5-358 
22b) and sensitive (10-26b, 1-28a) C. suis field strains from previous studies (Seth-Smith et 359 
al., 2017; Wanninger et al., 2016). As expected, we also observed that inclusion number and 360 
morphology of the three tetracycline resistant strains was not affected by tetracycline 361 
exposure while the two sensitive strains showed no or only micro-inclusions at 0.125 µg/ml 362 
and 0.5 µg/ml tetracycline (Fig. S1). In addition, we screened two human chlamydial strains, 363 
C. trachomatis serovar E and C. pneumoniae Kajaani 6, and confirmed their susceptibility to 364 
tetracycline, as indicated by the described inclusion size criteria, as expected (Fig. S2). 365 
 366 
Recovery assay 367 
Finally, we analyzed the infectivity of strains SWA-14, 86, 141 and S45/6, in terms of 368 
recovery, upon exposure to tetracycline followed by discontinuation of exposure to 369 
tetracycline versus uninterrupted, continuous exposure to tetracycline. Briefly, in parallel to 370 
the initial susceptibility phenotype, cultures were prepared for the recovery assay in 371 
cycloheximide-free medium. However, instead of fixation of the infected cells on coverslips, 372 
followed by immunofluorescence microscopic analysis to determine the phenotype, infected 373 
cells were washed two times with fresh medium, to remove residual drugs, and the medium 374 
was replaced with either medium alone (recovery, rec) or the same concentrations of 375 
tetracycline (continued exposure, exp) and incubated for another 48 h prior to scraping 376 
collection of infected cells to determine infectivity. In Week 2, in parallel to performing MIC 377 
confirmation, collected samples were inoculated onto fresh cells in cycloheximide-containing 378 
medium to determine the IFU/ml (see the Material and Methods section). The complete, 379 
detailed protocol is available in Text S1. 380 
We found that even tetracycline sensitive strains (SWA-14, 86, S45/6) are able to 381 
recover from tetracycline concentrations as high as 2 µg/ml, despite MIC values of 382 
0.125 µg/ml or less (Fig. 4). In contrast, no or only a minimal number of IFU (<0.001% of 383 
mock) were detectable following continued exposure to 0.5 and 2 µg/ml tetracycline for 384 
SWA-14, SWA-86 and S45/6, while the infectivity of SWA-141 cultures continuously 385 
exposed to 0.5 and 2 µg/ml was equivalent to 43.96% and 1.56% of the mock exposed 386 
infection, respectively. 387 
In order to concisely summarize the data (here for tetracycline exposure, also useful 388 
for analyses of other antibiotics) and provide descriptive characterization of the strains, we 389 
developed the following data analyses for the data (see Table 4): 1) “Resistance potential” 390 
(compares exposure to mock groups and represents the degree to which Chlamydia resist 391 
continuous exposure to the antibiotic in question) indicates the highest tetracycline 392 
concentration at which tetracycline exposed cultures exhibit infectivity equivalent to a) >25% 393 
or b) >10% of mock-exposed culture infectivity. 2) “Recovery potential” (compares recovery 394 
to mock groups and represents the degree to which Chlamydia recover from antibiotic 395 
exposure) indicates the highest antibiotic concentration at which cultures initially exposed to 396 
tetracycline, but then further cultured in the absence of tetracycline (recovered cultures), 397 
exhibit infectivity equivalent to a) >1% or b) >10% of mock-exposed culture infectivity. 398 
Lastly, 3) “Survival after continued exposure” (directly compares the infectivity of 399 
continuously tetracycline exposed cultures to recovered cultures [exposed to recovered 400 
groups]) indicates the highest antibiotic concentration at which continuously exposed cultures 401 
exhibit infectivity equivalent to a) >1% or b) >10% of recovered culture infectivity. The result 402 
of these analyses allowed clear differentiation between tetracycline resistant (SWA-141) and 403 
sensitive (SWA-14, SWA-86, and S45/6) strains (Table 4).  404 
 405 
Reference strain S45/6 is sensitive to sulfamethoxazole, while all tested C. suis field 406 
strains are sulfamethoxazole resistant 407 
 408 
Initial susceptibility phenotype, inclusion size analysis and MIC determination 409 
As for tetracycline, we aimed to analyze the susceptibility of the same four C. suis 410 
strains to sulfamethoxazole. However, determination of the initial susceptibility phenotype 411 
according to Donati et al. (2010) was not possible due to the fact that we only observed 412 
sulfamethoxazole-dependent changes in inclusion size/morphology, but no sulfamethoxazole-413 
dependent changes in the number of inclusions, even at concentrations as high as 512 µg/ml 414 
sulfamethoxazole compared to the mock-exposed control (Fig. S3A). As a result, initial 415 
susceptibility phenotype determination was performed only according to Suchland et al. 416 
(2003), resulting in MIC of 128-256 µg/ml, 64-128 µg/ml, 128-256 µg/ml and 0.0039 µg/ml 417 
for SWA-14, 86, 141 and S45/6, respectively. 418 
To confirm these MIC, we evaluated the average inclusion size per strain at 419 
sulfamethoxazole concentrations close to the initially determined MIC as performed for 420 
tetracycline. Fig. 5A illustrates the inclusion size differences allowing initial determination of 421 
MIC (per Suchland) and subsequent confirmation. The entire data set is summarized in 422 
Table 5.  423 
Interestingly, upon MIC confirmation, we observed that the three field strains exposed 424 
to sulfamethoxazole at their respective MIC (ranging from 64 to 256 µg/ml) universally 425 
contained smaller inclusions by immunofluorescence assay (IFA) compared to the mock-426 
exposed infection. Those inclusions appeared to contain large aberrant bodies (AB) indicative 427 
of the chlamydial stress response. In contrast, while a significant inclusion size reduction was 428 
apparent upon exposure to 0.0039 µg/ml sulfamethoxazole for reference strain S45/6, ABs 429 
were only sporadically present in the reference strain (Fig. 5A).  430 
 431 
Transmission electron microscopy (TEM) analysis of sulfamethoxazole-exposed cultures 432 
To confirm IFA observations regarding the presence of ABs, we performed TEM 433 
analysis (Fig. 5B). ABs were defined as pale, large inclusions of round to irregular shape with 434 
≥ 2µm in diameter (Matsumoto and Manire, 1970). While all mock-exposed cultures had 435 
inclusions primarily populated with small elementary bodies (EBs; dark, 0.25-0.5 µm in 436 
diameter) and reticulate bodies (RBs; pale, 0.5-1 µm in diameter), field strain cultures 437 
exposed to 128 µg/ml sulfamethoxazole contained inclusions populated with a large number 438 
of ABs or markedly altered RBs. In contrast, S45/6 cultures exposed to 0.015 µg/ml 439 
sulfamethoxazole contained a decreased number of EBs and RBs but no obvious increase in 440 
the number of ABs, confirming IFA results. 441 
 442 
Recovery assay 443 
Finally, we analyzed the infectivity of strains SWA-14, SWA-86, SWA-141 and S45/6 444 
in terms of recovery upon exposure to sulfamethoxazole followed by discontinuation of 445 
exposure to sulfamethoxazole versus continuous exposure to sulfamethoxazole. The assay 446 
was performed identically to the described tetracycline recovery assay. 447 
As expected from the initial susceptibility phenotype, wherein no sulfamethoxazole-448 
dependent inclusion number reduction was detected, all strains showed recovery up to 449 
512 µg/ml sulfamethoxazole though the number of IFU was distinctly reduced to only 0.18%, 450 
0.22%, 0.35% and < 0.001% of the control for SWA-14, 86, 141 and S45/6, respectively. 451 
While the general recovery pattern, as well as survival following continuous 452 
sulfamethoxazole exposure, was comparable for the three field strains, S45/6 showed a 453 
relative reduction of both parameters compared to the field strains (Fig. 6). This 454 
sulfamethoxazole susceptibility difference between the field strains and the type strain was 455 
even more pronounced when additional sulfamethoxazole concentrations were evaluated (2, 456 
8, 32, 128, 512 µg/ml sulfamethoxazole for field strains and 0.0039, 0.03, 0.25, 2, 8, 32, 128, 457 
512 µg/ml sulfamethoxazole for S45/6, Fig. S3B). 458 
Again, as for tetracycline analysis above, we compiled a table containing the following 459 
data of sulfamethoxazole analyses: 1) “resistance potential” (compares exposure to mock 460 
groups), 2) “recovery potential” (compares recovery to mock groups) and 3) “survival after 461 
continued exposure” (compares exposure to recovery groups). The results of these analyses 462 
allowed clear differentiation between sulfamethoxazole resistant field strains (SWA-14, 86, 463 
141) and the sulfamethoxazole sensitive reference strain S45/6 (Table 6).  464 
 465 
Penicillin G (PenG) induces the chlamydial stress response in C. suis strains 466 
 467 
Initial susceptibility phenotype, inclusion size analysis and MIC determination 468 
PenG is known to induce the chlamydial stress response or persistence in chlamydial 469 
species such as C. trachomatis and C. muridarum, the closest phylogenetic relatives of C. suis 470 
(Joseph et al., 2016; Kintner et al., 2014; Phillips Campbell et al., 2012; Seth-Smith et al., 471 
2017). In our study, we performed a PenG 10-fold serial dilution ranging from 0.001 to 472 
100 units (U)/ml PenG and observed that almost 100% of C. suis inclusions appeared to be 473 
altered in terms of morphology with the presence of ABs at almost all concentrations tested 474 
(0.1-100 U/ml for the field strains and 0.01-100 U/ml for S45/6, data not shown). At 475 
0.001 U/ml PenG, less than 90% of inclusions were aberrant in all evaluated strains. We 476 
subsequently performed MIC determinations while evaluating inclusion size and morphology 477 
at PenG concentrations of 1, 10 and 100 U/ml. Interestingly, while the inclusion morphology 478 
clearly showed signs of persistence in all four strains (SWA-14, SWA-86, SWA-141, S45/6) 479 
even at the lowest PenG concentration of 1 U/ml, the average inclusion size remained similar 480 
to that of the mock control (Fig. 7A). The observation of PenG-induced ABs in C. suis was 481 
confirmed by TEM comparing inclusions of S45/6 exposed to 1 U/ml and 100 U/ml PenG 482 
with the mock-exposed control. PenG-exposed C. suis inclusions consisted of mostly empty 483 
inclusions containing few ABs (Fig. S4A) as described recently for C. trachomatis and C. 484 
pecorum (Kintner et al., 2014; Leonard et al., 2016). 485 
 486 
Recovery assay 487 
As a final step, we analyzed the infectivity of strains SWA-14, SWA-86, SWA-141 488 
and S45/6 in terms of recovery upon exposure to PenG followed by discontinuation of 489 
exposure to PenG versus continuous exposure to PenG. Recovery assays were performed 490 
identically to the described tetracycline and sulfamethoxazole recovery assays. As expected, 491 
all the C. suis strains that were evaluated exhibited increased infectivity upon discontinuation 492 
of PenG exposure for 48 h, after 48 h of culture in the presence of PenG, compared to the 493 
continuous PenG-exposure group. Though the recovery group infectivity never exceeded 494 
0.001% of the infectivity of the unexposed control (which was inoculated with Chlamydia and 495 
cultured for 48 h in the absence of PenG exposure), discontinuation of PenG exposure for 48 496 
h resulted in infectivity levels 10-20 fold greater than those observed for cultures subjected to 497 
continuous PenG exposure for the same duration, indicative of recovery from PenG-induced 498 
infectivity reduction. Very little infectivity (<150 IFU/ml)/single inclusions were detected in 499 
the recovery assay for continuously exposed cultures for all PenG concentrations evaluated 500 
(Fig. 7B). Again, TEM analysis was performed for S45/6 to further demonstrate recovery 501 
after removal of PenG. When PenG exposure was discontinued after 48 h of exposure and 502 
culture was continued in the absence of PenG for 48 h, inclusions contained normal EBs and 503 
RBs, while continuously exposed cultures continued to contain only few inclusion bodies 504 
primarily consisting of ABs (Fig. S4B). 505 
 506 
 507 
Discussion 508 
While there are numerous standardized methods to evaluate extracellular and 509 
facultative intracellular bacteria regarding susceptibility to antibiotic agents, there are no 510 
standardized antibiotic susceptibility assays for Chlamydia. Instead, several research groups 511 
have, over time, developed multiple protocols to determine the antibiotic susceptibility of 512 
Chlamydia in vitro with microscopic methods as summarized in Table 1 (Agacfidan et al., 513 
1993; Donati et al., 2010; Ehret and Judson, 1988; Henning and Krauss, 1986; Japan Society 514 
of Chemotherapy, 1992a, 1992b; Suchland et al., 2003; Webberley et al., 1987). In addition to 515 
these classic in vitro susceptibility protocols, there are other systems such as antibiotic 516 
susceptibility in continuous-infection models instead of regular infection in vitro (Kutlin et 517 
al., 1999), in vitro susceptibility testing using flow cytometry instead of classic determination 518 
via microscopic reading (Dessus-Babus et al., 1998), and the use of a reverse transcriptase 519 
PCR (RT-PCR)-based method instead of inclusion number determination (Cross et al., 1999). 520 
Regardless of the applied method, a clear definition of the MIC and other evaluation 521 
parameters is needed to implement new approaches to determine the in vitro antibiotic 522 
susceptibility of Chlamydia. Although there has been no gold standard or consensus in the 523 
field for a standardized protocol for determination of antibiotic susceptibility and resistance, 524 
all research groups prior to 2000 defined the MIC as the lowest concentration where no 525 
inclusions were found (Agacfidan et al., 1993; Ehret and Judson, 1988; Hammerschlag, 1982; 526 
Henning and Krauss, 1986; Japan Society of Chemotherapy, 1992a, 1992b; Webberley et al., 527 
1987). More recent protocols from the 2000s included the principle of inclusion number 528 
reduction by 90% or more (Donati et al., 2010) or alterations in inclusion size and 529 
morphology (Suchland et al., 2003). Suchland and colleagues (2003) specifically noted that it 530 
might be problematic to define the MIC according to few survivors at high antibiotic 531 
concentrations (heterotypic survival), since micro-inclusions may not be visible depending on 532 
the staining/labeling method and magnification used. In view of these publications, we 533 
developed a consensus MIC considering previous MIC definitions according to Donati et al. 534 
(2010) and Suchland et al. (2003).  535 
Unlike already published protocols to determine the MIC, which are analyzed 536 
differently but processed analogously, the method to determine MBC/MCC/MLC strongly 537 
depends on the research group (Table 1). In detail, while one half of all research groups 538 
defined the MBC/MCC/MLC as the lowest concentration where there were no inclusions after 539 
passaging the strain once in drug-free medium (Agacfidan et al., 1993; Ehret and Judson, 540 
1988; Suchland et al., 2003; Webberley et al., 1987), the rest defined the MBC/MCC/MLC as 541 
the lowest antibiotic concentration where there were no or 90% fewer inclusions following re-542 
incubation in drug-free medium compared to the mock-exposed control (Donati et al., 2010; 543 
Henning and Krauss, 1986; Japan Society of Chemotherapy, 1992a, 1992b) Regardless of the 544 
protocol, all MBC/MCC/MLC protocols only determine one value, which is usually identical 545 
or only a few twofold dilutions higher compared to its MIC. In this study, in order to 546 
complement the MIC and to further characterize the chlamydial response to antibiotic 547 
exposure in vitro, we decided to employ the recovery assay, which has so far been described 548 
in studies investigating the chlamydial stress response (Kintner et al., 2014; Leonard et al., 549 
2015, 2017). With this recovery assay, instead of determining one single value that gives little 550 
additional information to the MIC, we evaluated low, intermediate, and high antibiotic 551 
concentrations for effects upon chlamydial infectivity after discontinuation of antibiotic 552 
exposure 48 hpi (recovery) or continued exposure for 96 h. Not only does it allow us to 553 
confirm the impact of inclusion size reduction on subsequent infectivity, it further implements 554 
the MBC/MCC/MLC (recovery) and expands previous protocols to observing infectivity upon 555 
continued exposure. 556 
In the present study, we evaluated the antibiotic susceptibility of three porcine field 557 
strains in comparison to the C. suis reference strain S45/6 (also of porcine origin) to 558 
tetracycline, sulfamethoxazole and penicillin. These antibiotic agents were chosen because of 559 
their extensive use in the pig farming industry (Hoffmann et al., 2015). Moreover, the 560 
presence of the tetracycline resistance gene tetA(C) has been reported in C. suis worldwide 561 
(USA, several European countries, Israel, China) (Borel et al., 2012; Dugan et al., 2004; Di 562 
Francesco et al., 2008; Joseph et al., 2016; Lenart et al., 2001; Li et al., 2017; Schautteet et al., 563 
2013; Seth-Smith et al., 2017; Wanninger et al., 2016). Therefore, tetracycline, a 564 
bacteriostatic protein synthesis inhibitor preventing the binding of bacterial aminoacyl-t-RNA 565 
to the mRNA-ribosome complex, is well suited as proof of concept for susceptibility assay 566 
development and evaluation, as there are clear, well-described features separating resistant 567 
from sensitive strains (Donati et al., 2010; Suchland et al., 2003). We further found that even 568 
sensitive strains are able to recover from tetracycline concentrations well above the MIC, 569 
which is indicative of heterotypic survival as reported by Suchland et al. (2003). Nonetheless, 570 
the observed infectivity pattern following recovery and continued exposure is markedly 571 
different between sensitive and resistant strains, which is expected based on the MIC data. 572 
With application of the initial susceptibility phenotype analysis that can be performed within 573 
two to three workdays and subsequent MIC confirmation that can completed within two to 574 
three additional workdays, we showed that a) simultaneous host cell seeding and chlamydial 575 
infection into culture medium with appropriate antibiotic dilutions yields similar results 576 
regarding susceptibility to more the time-consuming infection of confluent monolayers and 577 
that b) cycloheximide treatment does not appear to influence MIC determination. With data 578 
from this study and those of other research groups (Donati et al., 2016; Suchland et al., 2003), 579 
we established a fast and simple screening method to detect tetracycline resistant strains. Our 580 
Tet screen allows the evaluation of ten strains per 24-well plate within three days with 581 
minimal use of consumables where cultures are treated with 0.5 µg/ml tetracycline and 582 
compared to mock-exposed cultures. If inclusion size/morphology and number are similar to 583 
that of the corresponding tetracycline-unexposed mock control, the strain is considered to be 584 
tetracycline resistant. If there are no, or only small, aberrant inclusions, the strain is 585 
considered to be tetracycline sensitive. All “intermediate” stages, such as few but regular 586 
sized inclusions, should be processed further by a) determining the initial susceptibility 587 
phenotype, b) performing subsequent MIC confirmation and c) performing the recovery 588 
assays. So far, no “intermediate” stages were detected, but a larger sample size must be 589 
evaluated to further validate this method. 590 
Information regarding the susceptibility of C. suis to sulfonamides such as 591 
sulfamethoxazole, a bacteriostatic inhibitor of folate synthesis by competition with the 592 
substrate para-aminobenzoic acid (PABA) (Marwaha et al., 2014), is very limited. Reports 593 
generally state that C. suis appears to be sensitive to sulfonamides with the exception of a few 594 
tetracycline resistant strains (Andersen and Rogers, 1998; Sandoz and Rockey, 2010). These 595 
reports are contrary to our findings wherein all three field strains, of which two were sensitive 596 
to tetracycline, had sulfamethoxazole MICs of 64 µg/ml or higher. Moreover, MIC 597 
determination was only possible according to the MIC determination method by Suchland et 598 
al. (2003), because the inclusion number was not significantly influenced by 599 
sulfamethoxazole. Here, the recovery assay was crucial to confirm that the alteration in terms 600 
of size and morphology strongly impacted the infectivity upon recovery and continued 601 
exposure and therefore further served as a confirmation of the MIC. Interestingly, reporting 602 
results from a study on C. trachomatis, which defined the MIC as the concentration of 603 
sulfamethoxazole for which no inclusions are seen, the authors were able to determine 604 
susceptibilities for sulfamethoxazole in the range of 2 to 128 µg/ml (Hammerschlag, 1982). 605 
However, the authors specifically noted that only low inocula (≤ 1000 IFU) could be used to 606 
yield these results. Larger inocula did not yield an MIC according to their definition, but they 607 
showed a sulfamethoxazole concentration-dependent alteration in inclusion size and 608 
morphology. The susceptibility range (2-128 µg/ml) to sulfomethoxazole reported for C. 609 
trachomatis appears to be similar to that found for C. suis although the MIC of S45/6 was 610 
below 0.01 µg/ml. From the small number of strains investigated in our study, it appears that 611 
field strains are mostly resistant to sulfamethoxazole independent of resistance to tetracycline, 612 
while the C. suis type strain S45/6 is sulfamethoxazole sensitive. However, a larger sample 613 
size is necessary to confirm this finding. Moreover, these and other C. suis field strains should 614 
also be investigated for resistance to N-acylated sulfonamide derivatives because, despite 615 
sharing the structural core with sulfamethoxazole and sulfafurazole, they operate via a distinct 616 
working mechanism (Marwaha et al., 2014; Mojica et al., 2017): These antibiotics do not 617 
affect folate synthesis but instead bind directly to the 3-oxoacyl-(acyl carrier protein [ACP] 618 
synthase II [FabF]) thus inhibiting the essential type II fatty acid synthesis (FASII) pathway. 619 
Given that almost every chlamydial species evaluated to date responds with the 620 
chlamydial stress response upon treatment with  β-lactam antibiotics (Beatty et al., 1994; 621 
Galasso and Manire, 1961; Hogan et al., 2004; Matsumoto and Manire, 1970; Schoborg, 622 
2011; Tamura and Manire, 1968; Wyrick, 2010) with few exceptions (Dumoux et al., 2013), 623 
it is not surprising that all four investigated C. suis strains develop persistence from PenG 624 
treatment. However, while this in vitro assay allowed us to detect and describe persistence in 625 
our cultures, more appropriate protocols are available to investigate the chlamydial stress 626 
response (Kintner et al., 2014; Leonard et al., 2015, 2016, 2017). Nevertheless, we showed 627 
that C. suis could recover from PenG exposure in a similar manner to C. trachomatis, though 628 
infectivity was reduced by more than 99% upon exposure to 1 U/ml in both chlamydial 629 
species (Kintner et al., 2014). Interestingly, while TEM analysis in the C. trachomatis study 630 
revealed large ABs that filled the inclusion after exposure with penicillin, we found few 631 
grossly enlarged ABs that did not fill the entire inclusion. Ultrastructural differences in the 632 
chlamydial stress response are primarily caused by different persistence inducers, host cells 633 
and the Chlamydia species (Goellner et al., 2006; Hogan et al., 2004; Mukhopadhyay et al., 634 
2006; Schoborg, 2011). Therefore, host cells (HeLa vs. LLC-MK2) or the chlamydial species 635 
(C. trachomatis vs. C. suis) may have caused the ultrastructural differences in this study 636 
compared to Kintner et al. (Kintner et al., 2014). In contrast, HeLa cells infected with the 637 
porcine C. pecorum strain 1710S and PenG-exposed (Leonard et al., 2016, 2017) revealed 638 
similar inclusions to those present in PenG-exposed C. suis strains described in this study. 639 
One of the limitations of our study is that we did not test our protocols using different 640 
host cells, unlike previous reports from other authors (Ehret and Judson, 1988; Suchland et 641 
al., 2003). Suchland et al. (2003) found that there are notable differences regarding the MIC 642 
for macrolides (azithromycin, erythromycin) for Chlamydia spp. depending on the cell line 643 
used, for example McCoy, HeLa, BGMK, HEp-2, HL, or Vero cells. But the same was not 644 
shown for tetracycline, ofloxacin and doxycycline. The authors proposed that McCoy cells 645 
should be consistently used for C. trachomatis and HEp-2 for C. pneumoniae antibiotic 646 
susceptibility assays. So far, there is no specific recommendation for C. suis but McCoy, 647 
BGM and LLC-MK2 cells have all been successfully used for isolation and antibiotic 648 
susceptibility assays (Donati et al., 2010; Dugan et al., 2004; Schautteet et al., 2013). For 649 
tetracyclines, cell-specific differences likely play a minor role as observed for C. trachomatis 650 
(Suchland et al., 2003), but no comparable study similar to that of Suchland et al. (2003) has 651 
been conducted for C. suis so far. Other potentially relevant factors not assessed in this study 652 
include medium constituents, incubation conditions and centrifugation protocols as well as 653 
timing/duration of antibiotic exposure and immunolabeling of inclusions (Giemsa, iodine, 654 
immunofluorescence) (Ehret and Judson, 1988). Additionally, the inoculum size is generally 655 
considered irrelevant for MIC determination but could influence the recovery assay if the 656 
inoculum size is below 5000 IFU/well (Suchland et al., 2003). 657 
Furthermore, our study has primarily focused on the classic microscopic reading 658 
methods. In the future, it is vital consider alternative methods that were first published in the 659 
late 1990s such as the RT-PCR method (Cross et al., 1999). They found that smaller and/or 660 
aberrant inclusions still produce detectable levels of mRNA and are therefore potentially 661 
viable further supporting the results of the recovery assay applied in this study and the high 662 
MBC/MCC/MLC values from other protocols (Agacfidan et al., 1993; Donati et al., 2010; 663 
Ehret and Judson, 1988; Henning and Krauss, 1986; Japan Society of Chemotherapy, 1992a, 664 
1992b; Suchland et al., 2003; Webberley et al., 1987). Another method is the use of flow 665 
cytometry (Dessus-Babus et al., 1998), which was not considered to be as sensitive as the 666 
direct microscopic assessment method but still needs to be considered for its reproducibility 667 
and objective interpretation. Additionally, flow cytometry must be considered as a potential 668 
titration method (Käser et al., 2016) for the recovery assay as it has shown to be highly 669 
reproducible, faster with lower material cost than traditional titration methods.  670 
In summary, we propose new approaches to evaluate the antibiotic susceptibility of 671 
C. suis and other Chlamydia spp. by creating a consensus MIC based on inclusion number 672 
reduction and size/morphology alteration. This approach allows the determination of a 673 
susceptibility range for antibiotic agents and chlamydial species that have not been tested so 674 
far. Finally, we propose a simple and fast screening method to detect tetracycline resistant 675 
C. suis strains. 676 
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 900 
901 
Figure Legends 902 
 903 
Figure 1. Overview of the in vitro antibiotic susceptibility assay protocol. Shown is an 904 
overview of the in vitro assay protocol grouped into the first and second week of the assay 905 
and divided into initial susceptibility phenotype/MIC confirmation and the recovery assay. 906 
 907 
Figure 2. Average inclusion size analysis upon tetracycline exposure. The bar graphs 908 
compare the average inclusion size (µm2) of unexposed controls (mock) with tetracycline-909 
exposed (0.03, 0.125 and 0.5 µg/ml) cultures at 34 hours post infection (mean ± SD). Shown 910 
are the results for strains A) SWA-14, B) SWA-86, C) SWA-141 and D) reference strain 911 
S45/6. Asterisks indicate a statistically significant difference between the tetracycline-912 
exposed cultures and the mock by both Student’s t-test and the Welch t-test (ns = not 913 
significant; * p < 0.05; ** p < 0.01). Three independent experiments were performed (n = 3); 914 
0.125 and 0.5 µg/ml tetracycline were only evaluated in two of the three experiments (n = 2).  915 
 916 
Figure 3. Tetracycline resistance screen of strains SWA-14, 86, 141 and S45/6. Shown are 917 
immunofluorescence images illustrating the results of the tetracycline resistance screen (TET 918 
Screen) wherein inclusion number and morphology of mock-exposed chlamydial strains are 919 
compared to cultures exposed to 0.125 or 0.5 µg/ml tetracycline. The white bar represents 920 
50 µm. 921 
 922 
Figure 4. Recovery assay following chlamydial infection and tetracycline exposure. The 923 
bar graphs compare the average inclusion forming units per ml (IFU/ml) of unexposed 924 
controls (mock) with tetracycline-exposed (0.03, 0.5 or 2 µg/ml) chlamydial cultures (mean ± 925 
SD). Cultures were either continuously exposed (exp) to tetracycline for 96 hours (h) or 926 
exposed to tetracycline for 48 h, then further cultured in tetracycline-free medium for 48 h 927 
(recovery, rec). Shown are the results for strains A) SWA-14, B) SWA-86, C) SWA-141 and 928 
D) reference strain S45/6. Three independent experiments were performed (n = 3). 929 
 930 
Figure 5. The effects of sulfamethoxazole exposure. A) Shown are bar graphs comparing 931 
the average inclusion size of sulfamethoxazole-treated cultures to the mock-exposed cultures 932 
(left; mean ± SD) as well as representative immunofluorescence images of the inclusion 933 
morphology of the untreated control (right, top) and the MICTP (right, bottom) for strains 934 
SWA-14, SWA-86, SWA-141 and S45/6 at 48 hours (h) post infection. Asterisks indicate a 935 
statistically significant difference between the sulfamethoxazole-exposed cultures and the 936 
mock by both Student’s t-test and the Welch t-test (ns = not significant; * p < 0.05; ** 937 
p < 0.01). Three independent experiments were performed (n = 3). B) Representative 938 
transmission electron microscopy (TEM) images are shown for each strain wherein the mock 939 
is presented on the left part of the panel and sulfamethoxazole-exposed cultures are presented 940 
on the right. Inclusions are indicated in green (I), the nucleus in dark red (N) and, if 941 
applicable, the nucleolus in bright red (Nc). Cultures were fixed at 48 h post infection for 942 
processing for TEM analysis. 943 
 944 
Figure 6. Recovery assay following chlamydial infection with sulfamethoxazole 945 
exposure. The bar graphs compare the average inclusion forming units per ml (IFU/ml) of 946 
unexposed controls (mock) with sulfamethoxazole-exposed (2, 32 and 512 µg/ml) cultures 947 
(mean ± SD). Cultures were either continuously exposed (exp) to sulfamethoxazole for 96 948 
hours (h) or exposed to sulfamethoxazole for 48 h, then further cultured in sulfamethoxazole-949 
free medium for 48 h (recovery, rec). Shown are the results for strains A) SWA-14, B) SWA-950 
86, C) SWA-141 and D) reference strain S45/6. Three independent experiments were 951 
performed (n = 3). 952 
 953 
Figure 7. Penicillin G induces the chlamydial stress response in all C. suis strains. A) 954 
Shown are bar graphs comparing the average chlamydial inclusion size of Penicillin G 955 
(PenG)-exposed cultures to the mock-exposed control (left; mean ± SD) as well as 956 
representative immunofluorescence microscopy images of inclusion morphology of both the 957 
unexposed control (right, top) and cultures exposed to 1 units (U)/ml of PenG (right, bottom) 958 
for strains SWA-14, SWA-86, SWA-141 and S45/6 at 48 hours (h) post infection. Two 959 
independent experiments were performed (n = 2). Asterisks indicate a statistically significant 960 
difference between the PenG-exposed cultures and the mock by both Student’s t-test and the 961 
Welch t-test (ns = not significant; * p < 0.05; ** p < 0.01). B) The bar graphs compare the 962 
average inclusion forming units per ml (IFU/ml) of unexposed controls (mock) with PenG-963 
exposed (1, 10 and 100 U/ml) cultures (mean ± SD). Cultures continuously exposed to PenG 964 
for 96 h (exp) were compared with cultures exposed to PenG for 48 h and then further 965 
cultured in PenG-free medium for 48 h (recovery, rec). Shown are the results for strains 966 
SWA-14 (top left), SWA-86 (top right), 141 (bottom left) and the reference strain S45/6 967 
(bottom right). Two independent experiments were performed (n = 2). 968 
 969 
Supplementary Material 970 
Figure S1. Tetracycline resistance screen of additional C. suis field strains. Shown are 971 
immunofluorescence images illustrating the results of the tetracycline resistance screen (TET 972 
Screen) where inclusion number and morphology of mock-exposed chlamydial strains are 973 
compared to cultures exposed to 0.125 or 0.5 µg/ml tetracycline. Strains used in this 974 
experiment were previously analyzed according to the Donati method (Donati et al. 2010. 975 
Antimicrob. Agents Chemother. doi:10.1128/AAC.00553-10), as reported in (Wanninger et al. 976 
2016. Plos One. doi: 10.1371/journal.pone.0166917). In the previous study, 10-26b was 977 
interpreted as sensitive to tetracycline, 5-27b and 5-22b as resistant to tetracycline. Also 978 
during the course of the previous study, strains 1-28a and 1-28b were also determined as 979 
sensitive and resistant, respectively (unpublished data). The respective absence and presence 980 
of the tetracycline resistance gene was confirmed in a follow-up comparative genomics study 981 
(Seth-Smith et al. 2017. Genome Biol Evol. doi: 10.1093/gbe/evx043. ENA deposition 982 
PRJEB17986). 983 
 984 
Figure S2. Tetracycline resistance screen of human-infecting pathogens, C. trachomatis 985 
serovar E and C. pneumoniae Kajaani 6 (K6). Shown are immunofluorescence images 986 
illustrating the results of the tetracycline resistance screen (TET Screen) wherein inclusion 987 
number and morphology of mock-exposed chlamydial strains are compared to cultures 988 
exposed to 0.125 or 0.5 µg/ml of tetracycline. Strains used in this experiment were two 989 
reference strains, a human genital strain C. trachomatis (Ct) serovar E, originally obtained 990 
from S. P. Wang and C. C. Kuo (University of Washington, Seattle, WA, USA; Holt et al. 991 
1967. Am J Ophalmol) and the human C. pneumoniae (Cp) Kajaani 6 (K6) strain (kindly 992 
provided by Dr Claudia Dumrese and Dr Urs Ziegler, Center for Microscopy and Image 993 
analysis, University of Zurich, Switzerland). Neither strain is positive for the tetracycline 994 
resistance gene (ENA deposition PRJEB17986). 995 
 996 
Figure S3. Additional analyses for sulfamethoxazole exposure. A) The bar graphs show 997 
the average inclusion number reduction upon exposure of cultures to 256 or 512 µg/ml 998 
sulfamethoxazole (SULF), expressed as percent of the mock-exposed control (mean ± SD). B) 999 
The bar graphs compare the mean inclusion forming units per ml (IFU/ml) of unexposed 1000 
controls (mock) with sulfamethoxazole-exposed Chlamydia cultures (2, 8, 32, 128 and 512 1001 
µg/ml SULF for the field strains and additionally 0.0039, 0.03 and 0.25 µg/ml SULF for the 1002 
reference strain S45/6; mean ± SD). Cultures continuously exposed (exp) to sulfamethoxazole 1003 
for 96 hours (h) were compared with cultures grown for 48 h in SULF-free medium after 48 h 1004 
of exposure to SULF (recovery, rec). Shown are the results for strains SWA-14 (top left 1005 
panel), SWA-86 (top right), 141 (bottom left) and reference strain S45/6 (bottom right). Three 1006 
independent experiments were performed (n = 3). 1007 
 1008 
Figure S4. Transmission electron microscopy (TEM) analysis of Penicillin G exposure in 1009 
C. suis strain S45/6. A) Shown is the inclusion morphology of the reference strain S45/6 39 1010 
hours (h) post infection for mock-exposed cultures (left), cultures treated with 1 U/ml 1011 
(middle) and 100 U/ml (right) Penicillin G (PenG). The scale bar indicates 5 µm. B) A 1012 
recovery assay was performed for the mock (no PenG) and 1 U/ml PenG groups. At 39 h post 1013 
infection, antibiotic-free (mock) or PenG-containing (1 U/ml) supernatant was removed from 1014 
the monolayer and replaced with PenG-free (mock, recovery) or PenG-containing (continued 1015 
exposure) medium. At 87 h, cultures were fixed and further processed for TEM analysis. The 1016 
scale bar indicates 5 µm. 1017 
 1018 
Text S1. Complete in vitro antibiotic susceptibility assay protocol. Shown is the detailed 1019 
protocol for the complete in vitro assay for tetracycline, sulfamethoxazole and penicillin. In 1020 
addition, suggestions regarding assay optimization are included. 1021 
 1022 
1023 
Table 1: List of reported antibiotic susceptibility assays 1024 
Group/Ref Definition of minimal inhibitory concentration 
(MIC) and minimal bactericidal/chlamydicidal/lethal 
concentration (MBC/MCC/MLC) 
Cells Species 
Suchland et al. 
(2003) 
MIC: “The transition point MIC (MICTP) was defined 
as the concentration of drug in which 90% or more of 
the inclusions were altered in size and morphology. 
The MIC was defined as the concentration of drug that 
is one twofold dilution more concentrated than the 
MICTP.” (p. 637) 
MCC: “The lowest concentration of drug that produced 
no morphologically normal inclusions by one freeze-
thaw passage (…) in antimicrobial-free medium.” (p. 
637) 
HeLa, 
BGMK, 
HEp-2, 
Vero 
CT1, 
Cpsi2, 
Cpne3 
Donati et al. 
(2010) 
MIC: “The lowest concentration that reduced the 
number of inclusions more than 90% compared with 
the level for drug-free controls.” (p. 5380) 
MBC: “The MBC concentration was measured by 
aspirating the antibiotic-containing medium, washing 
the monolayer twice with PBS, and incubating it in (…) 
antibiotic-free medium for 48 hours (h) at 35°C. (…). 
The MBC was the lowest concentration of the drug 
reducing more than 90% demonstrable inclusions 
after monolayers were re-incubated in antimicrobial-
free medium.” (p. 5380) 
LLC-
MK2 
CT1 
Japan Society of 
Chemotherapy 
(1992a, 1992b) 
MIC: “The lowest concentration, which completely 
inhibits inclusion body formation.” (p. 309) 
MLC: “The lowest concentration, which completely 
inhibits the reformation of chlamydial inclusion in 
infected HeLa 229 cells even after elimination of the 
drug from the culture medium (after 24 h).” (p. 318) 
HeLa, 
McCoy 
CT1, 
Cpsi2, 
Cpne3 
Ehret and 
Judson (1988), 
Hammerschlag 
(1982) 
MIC: “The MIC should be defined as no inclusions 
seen.” (Ehret, p. 1298; Hammerschlag, p. 500) 
MBC: “(…) the MBC should be defined as no 
inclusion seen on passaging.” (Ehret, p. 1298) 
McCoy CT1 
Webberley et al. 
(1987) 
MIC: “The MIC was defined as the lowest 
concentration of antibiotic that inhibited inclusion 
development after 48 h.” (p. 409) 
MLC: “(…) the lowest concentration that prevented 
the reappearance of inclusions after re-incubation in 
antibiotic free media.” (p. 409) 
McCoy Cpne3 
Schachter et al. 
(Agacfidan et 
al., 1993) 
MIC: “The MIC for Chlamydia was defined as the 
concentration of antibiotic that allowed no inclusions 
on the first passage.” (p. 1993) 
MCC: “The MCC was defined as the lowest 
concentration that allowed no inclusions in a further 
passage in the absence of antibiotics.” (p. 1993) 
McCoy CT1 
Henning and 
Krauss (1986) 
MIC (MHK, Minimale Hemmkonzentration): “The 
lowest concentration where there are no inclusions.” (p. 
448) 
MBC (Washed and reincubated, W & R): “The 
BGM, 
McCoy 
Cpsi2 
lowest concentration of drug that produced no 
inclusions after removal of the drug and several 
washing steps during incubation in drug-free medium.” 
(p. 448) 
1 C. trachomatis, 2 C. psittaci, 3 C. pneumoniae 1025 
 1026 
 1027 
Table 2: Overview of Chlamydia suis strains used in this study 1028 
Sample ID 
Year of 
Isolation, 
country of 
origin 
Antibiotic 
treatment of 
pig 
ENA deposition Ref 
SWA-14  
(alt. 2-7 a R) 
2013, 
Switzerland unknown PRJEB17986 This study 
SWA-86 2013, Switzerland unknown PRJEB17986 This study 
SWA-141  
(alt. 4-29 b R) 
2013, 
Switzerland tetracycline PRJEB17986 
(Seth-Smith et 
al., 2017; 
Wanninger et al., 
2016) 
S45/6 (ref) 1960s, Austria unknown SRP076849   
(Joseph et al., 
2016; 
Kaltenboeck et 
al., 1993) 
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Table 3: Summary of the initial MIC determination (tetracycline) 1031 
Week 1 SWA-14 SWA-86 SWA-141 S45/6 
MIC (per Donati) 0.03 µg/ml 0.03 µg/ml 4 µg/ml 0.06 µg/ml 
Week 2 SWA-14 SWA-86 SWA-141 S45/6 
MIC (per Donati) 0.06 µg/ml 0.03 µg/ml 4 µg/ml 0.125 µg/ml 
MIC (per Suchland) 0.06 µg/ml 0.03 µg/ml 4 µg/ml 0.06-0.125 µg/ml 
MIC consensus 0.03-0.06 µg/ml 0.03 µg/ml 4 µg/ml 0.06-0.125 µg/ml 
Interpretation sensitive sensitive resistant sensitive 
 1032 
Table 4: Summary of the recovery assay (tetracycline), strain characterization 1033 
1) Exposure to mock 
Resistance potential SWA-14 SWA-86 SWA-141 S45/6 
>25% <0.03 µg/ml <0.03 µg/ml 0.5 µg/ml <0.03 µg/ml 
>10% <0.03 µg/ml <0.03 µg/ml 0.5 µg/ml 0.03 µg/ml 
2) Recovery to mock 
Recovery potential SWA-14 SWA-86 SWA-141 S45/6 
>10% <0.03 µg/ml <0.03 µg/ml 0.5 µg/ml 0.03 µg/ml 
>1% 0.03 µg/ml <0.03 µg/ml 2 µg/ml 0.03 µg/ml 
3) Exposure to recovery 
Survival post exposure SWA-14 SWA-86 SWA-141 S45/6 
>10% <0.03 µg/ml <0.03 µg/ml 2 µg/ml 0.03 µg/ml 
>1% <0.03 µg/ml <0.03 µg/ml 2 µg/ml 0.03 µg/ml 
Interpretation  sensitive sensitive resistant sensitive 
 1034 
Table 5: Summary of the MIC determination (sulfamethoxazole) 1035 
 SWA-14 SWA-86 SWA-141 S45/6 
Initially 
determined MIC 128-256 µg/ml 64-128 µg/ml 128-256 µg/ml 0.0039 µg/ml 
MIC confirmation 256 µg/ml 64-128 µg/ml 128-256 µg/ml 0.0078 µg/ml 
MIC consensus 128-256 µg/ml 64-128 µg/ml 128-256 µg/ml 0.0039-0.0078 µg/ml 
Interpretation resistant resistant resistant sensitive 
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Table 6: Summary of the recovery assay (sulfamethoxazole), strain characterization 1038 
1) Exposure to mock 
Resistance potential SWA-14 SWA-86 SWA-141 S45/6 
>25% < 2 µg/ml < 2 µg/ml 2 µg/ml < 0.0039 µg/ml 
>10% 2 µg/ml 2 µg/ml 2 µg/ml < 0.0039 µg/ml 
2) Recovery to mock 
Recovery potential SWA-14 SWA-86 SWA-141 S45/6 
>10% 2 µg/ml 2 µg/ml 2 µg/ml < 0.0039 µg/ml 
>1% 32 µg/ml 2 µg/ml 32 µg/ml 0.0039 µg/ml 
3) Exposure to recovery 
Survival post exposure SWA-14 SWA-86 SWA-141 S45/6 
>10% 2 µg/ml 2 µg/ml 2 µg/ml < 0.0039 µg/ml 
>1% 2 µg/ml 32 µg/ml  2 µg/ml 0.0039 µg/ml 
Interpretation  resistant resistant resistant sensitive 
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